Leadership & Pay ·
On August 7, 2026, OnKure Therapeutics repriced approximately 1.7 million underwater stock options held by employees…
OKUROnKure Therapeutics, Inc.
On August 7, 2026, OnKure Therapeutics repriced approximately 1.7 million underwater stock options held by employees and consultants to a new exercise price of $4.14 per share, matching the closing stock price on that date. The repricing applied to options granted prior to January 1, 2025, with original exercise prices between $13.99 and $24.59. Named executive officers Nicholas Saccomano, Samuel Agresta, and Jason Leverone received repriced options covering 863,121 shares combined. Retention requirements mandate continued service for 18 months for senior management or one year for other employees; failure to meet these terms triggers a premium exercise price equal to the original strike. This action aims to retain talent without incurring additional dilution from new grants or cash compensation costs. OnKure Therapeutics operates in the biotechnology industry, focusing on developing novel therapies.